Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

NCT03133234 · clinicaltrials.gov ↗

COMPLETED

Status

47

Enrollment

INDUSTRY

Sponsor class

Conditions

T790M Positive NSCLC Patients

Interventions

DRUG: osimertinib

Sponsor

AstraZeneca